Von Willebrand factor modulates factor VIII immunogenicity: Comparative study of different factor VIII concentrates in a haemophilia A mouse model

Thrombosis and Haemostasis

Volumn 88, Issue 2, 2002, Pages 221-229

  Behrmann, Mathias ^a   Pasi, John ^a   Saint Remy, Jean Marie R ^a   Kotitschke, Ronald ^a   Kloft, Michael ^a  

^a BIOTEST AG   (Germany)

Author keywords

Animal model; Factor VIII; Haemophilia A; Immunogenicity; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; EPITOPE; HAEMATE; HAEMOCTIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; ASSAY; CONTROLLED STUDY; EPITOPE MAPPING; ESCHERICHIA COLI; HEMOPHILIA A; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RISK FACTOR; SUBSTITUTION THERAPY;

EID: 0036332175     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613191     Document Type: Article

References (44)

1. Structure of human factor VIII
2. The life cycle of coagulation factor VIII in view of its structure and function
3. Isolation and characterization of human factor VIII: Molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma
4. r-80.000 light chain
5. A role for the C2 domain of factor VIII in binding to von Willebrand factor
6. Inactivation of human factor VIII by activated protein C: Cofactor activity of protein S and protective effect of von Willebrand factor
7. The effect of von Willebrand factor on activation of factor VIII by factor Xa
8. Incidence of inhibitors in haemophilia A patients - A review of recent studies of recombinant and plasma-derived factor VIII concentrates
9. Factor VIII inhibitor IgG subclass and fVIII polypeptide specificity determined by immunoblotting
10. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction
11. Inhibition of human factor VIIIa by anti-A2 subunit antibodies
12. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli
13. 1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor
14. Antibodies to factor VIII in hemophilia A patients
15. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands
16. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
17. Inhibitors in German haemophilia A patients treated with a double virus inactivated factor VIII concentrate bind the C2 domain of FVIII light chain
18. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
19. Inactivation of factor VIII by factor IXa
20. A more uniform measurement of factor VIII inhibitors
21. Mechanism and kinetics of factor VIII inactivation: Study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor
22. An improved procedure for the purification of protein fused with glutathione S-transferase
23. Recombinate®; Viral safety and final product manufacturing testing and specifications
24. A novel cause of mild/moderate hemophilia A: Mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor
25. Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model
26. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies
27. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A
28. Mechanism of the immune response to human factor VIII in murine hemophilia A
29. Epidemiology of inhibitor development in haemophilia a patients treated with virus-inactivated plasma-derived clotting factor concentrates
30. Inhibitor antibody development and T cell response to human factor VIII in murine Hemophilia A
31. Degradation products of factor VIII which can lead to increased immunogenicity
32. Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells
33. Effect of factor VIII concentrate on leucocyte cytokine production: Characterization of TGF-β as an immunomodulatory component in plasma-derived factor VIII concentrate
34. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor
35. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII
36. Some factor VIII (fVIII) inhibitors recognise a fVIII epitope(s) that is present only on fVIII-VWF complexes
37. A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic
38. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor
39. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies
40. Humanized severe combined immunodeficient mice as a potential model for the study of tolerance to factor VIII
41. Kinetics of factor VIII- von Willebrand factor association
42. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation
43. Molecular modifications in factor VIII concentrates produced from different plasma pools
44. Phospholipid binding of factor VIII in different therapeutic concentrates